Inspire Medical Systems, Inc. INSP
NYSE · United States · Health Technology
$70.78+1.42 (+2.05%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the American Medical Association (AMA) CPT® Editorial Panel has approved the establishment of a new set of Current Procedural Terminology (CPT®) codes that accurately describe and include the Inspire V syste
Inspire Medical Systems has seen its share price fall sharply over several years, and that slide raises a pointed question about whether the current market value still lines up with the cash the business is expected to generate. With the stock now well below past peaks, the key issue is how today’s US$69.36 price compares with its future cash flow profile. The share price decline of 71.2% over 5 years puts long term expectations for Inspire Medical Systems’ cash generation under the...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Inspire Medical Systems (INSP) has been drawing attention after a sharp move in its share price, with the stock last closing at US$70. That shift is prompting fresh questions about how investors are treating this sleep apnea specialist. Recent trading tells a mixed story for Inspire Medical Systems. The share price has surged with a 56.9% 90 day return and 13.9% 1 month gain; yet momentum is fading near term with the 7 day share price return down 7.6% and the year to date share price return...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.